



## TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting

March 15, 2018

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that preclinical data for TG-1601, the Company's novel BET inhibitor, has been selected for presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 14 - 18, 2018, at McCormick Place North/South in Chicago, Illinois.

The presentation details are as follows:

- Title: [TG-1601 is a novel BET inhibitor with strong binding affinity and long-lasting effect in pre-clinical models](#)
  - Abstract Number: 5790
  - Date and Time: Wednesday, April 18, 2018:00 AM - 12:00 PM (CT)
  - Session Category/Title: Experimental and Molecular Therapeutics/ Canonical Targets 2
  - Location: McCormick Place South, Exhibit Hall A, Poster Section 36
  - Poster Board Number: 16

A copy of the above referenced abstract can be viewed online through the AACR meeting website at [www.aacr.org](http://www.aacr.org). Following the presentation, the data presented will be available on the Publications page of the Company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com).

### ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both ublituximab and umbralisib, the combination of which is referred to as 'U2', are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.

### Cautionary Statement

Some of the statements included in this press release or in the abstract, particularly those anticipating future clinical trials, attributes, business prospects and/or potential use of TG-1601, the company's BET inhibitor, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to identify a BET inhibitor suitable for clinical development, our ability to successfully and cost-effectively complete preclinical and clinical trials; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior preclinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at [www.tgtherapeutics.com](http://www.tgtherapeutics.com). The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

### CONTACT:

Jenna Bosco  
SVP, Corporate Communications  
TG Therapeutics, Inc.  
Telephone: 212.554.4351  
Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

[Primary Logo](#)

Source: TG Therapeutics, Inc.